885278-18-2 Usage
Description
N-METHOXY-N-METHYL-THIAZOLE-2-CARBOXAMIDE is a chemical compound with the molecular formula C7H10N2O2S. It is a derivative of the thiazole ring and contains both a methoxy and a methyl group. N-METHOXY-N-METHYL-THIAZOLE-2-CARBOXAMIDE is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds.
Used in Pharmaceutical Industry:
N-METHOXY-N-METHYL-THIAZOLE-2-CARBOXAMIDE is used as an intermediate in the synthesis of pharmaceuticals for its ability to interact with biological targets such as enzymes and receptors, playing a crucial role in medicinal chemistry and drug development.
Used in Organic Chemistry:
N-METHOXY-N-METHYL-THIAZOLE-2-CARBOXAMIDE is used as a building block in the synthesis of various organic molecules, contributing to the development of new compounds with potential applications in different fields.
Used in Agricultural Applications:
N-METHOXY-N-METHYL-THIAZOLE-2-CARBOXAMIDE may have potential uses in agriculture, although specific applications are not detailed in the provided materials. Its role could be related to the development of new agrochemicals or as a component in existing products.
Used in Industrial Applications:
Similarly, N-METHOXY-N-METHYL-THIAZOLE-2-CARBOXAMIDE may also have potential uses in industrial applications, although the specific uses are not provided in the materials. Its applications could be related to the synthesis of industrial chemicals or materials.
Check Digit Verification of cas no
The CAS Registry Mumber 885278-18-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 8 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 885278-18:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*8)+(2*1)+(1*8)=222
222 % 10 = 2
So 885278-18-2 is a valid CAS Registry Number.
885278-18-2Relevant articles and documents
Selective Class i HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance
Barnard, Richard J. O.,Carroll, Steve,Chung, Christine C.,Clausen, Dane,Duffy, Joseph L.,Fells, James,Holloway, M. Katharine,Howell, Bonnie J.,Kelly, Joseph,Kim, Hyunjin,Klein, Daniel J.,Kozlowski, Joseph A.,Liu, Jian,Myers, Robert W.,Wu, Guoxin,Wu, Jin,Yu, Wensheng,Yu, Younong
supporting information, p. 1476 - 1483 (2020/07/31)
HIV persistence in latently infected, resting CD4+ T cells is broadly considered a barrier to eradicate HIV. Activation of the provirus using latency-reversing agents (LRAs) followed by immune-mediated clearance to purge reservoirs has been touted as a promising therapeutic approach. Histone deacetylases (HDACs) and histone acetyltransferases (HATs) control the acetylation level of lysine residues in histones to regulate the gene transcription. Several clinical HDAC inhibitors had been examined as LRAs, which induced HIV activation in vitro and in vivo. Here we report the discovery of a series of selective and potent class I HDAC inhibitors based on aryl ketones as a zinc binding group, which reversed HIV latency using a Jurkat model of HIV latency in 2C4 cells. The SAR led to the discovery of a highly selective class I HDAC inhibitor 10 with excellent potency. HDACi 10 induces the HIV gag P24 protein in patient latent CD4+ T cells.
